The Extrapituitary Effects of GnRH Antagonists and Their Potential Clinical Implications: A Narrated Review

被引:13
作者
Tan, Orkun [1 ]
Carr, Bruce R. [1 ]
Beshay, Victor E. [1 ]
Bukulmez, Orhan [1 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, Dallas, TX 75390 USA
关键词
GnRH types; GnRH receptors; GnRH antagonist; implantation; endometrium; ovary; heart; controlled ovarian stimulation; GONADOTROPIN-RELEASING-HORMONE; CONTROLLED OVARIAN STIMULATION; ANDROGEN DEPRIVATION THERAPY; BREAST-CANCER CELLS; PROSTATE-CANCER; RECEPTOR GENE; CARDIOVASCULAR-DISEASE; MOLECULAR-BIOLOGY; HUMAN ENDOMETRIAL; OOCYTE DONORS;
D O I
10.1177/1933719112459244
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Potential roles of gonadotropin-releasing hormone (GnRH) antagonists on GnRH/GnRH receptor systems and their effects on the extrapituitary tissues are largely elusive. In this narrated review, we summarized the systemic effects of GnRH antagonists on ovary, endometrium, embryo implantation, placental development, fetal teratogenicity, reproductive tissue cancer cells, and heart while briefly reviewing the GnRH and GnRH receptor system. GnRH antagonists may have direct effects on ovarian granulosa cells. Data are conflicting regarding their effects on endometrial receptivity. The GnRH antagonists may potentially have detrimental effect on early placentation by decreasing the invasive ability of cytotrophoblasts if the exposure to them occurs during early pregnancy. The GnRH antagonists were not found to increase the rates of congenital malformations. Comparative clinical data are required to explore their systemic effects on various extrapituitary tissues such as on cardiac function in the long term as well as their potential use in other human cancers that express GnRH receptors.
引用
收藏
页码:16 / 25
页数:10
相关论文
共 88 条
[1]   Gonadotrophin-releasing hormone antagonists for assisted conception: A Cochrane Review [J].
Al-Inany, H. G. ;
Abou-Setta, A. M. ;
Aboulghar, M. .
REPRODUCTIVE BIOMEDICINE ONLINE, 2007, 14 (05) :640-649
[2]   GnRH antagonists are safer than agonists: an update of a Cochrane review [J].
Al-Inany, Hesham G. ;
Youssef, Mohamed A. F. M. ;
Aboulghar, Mohamed ;
Broekmans, Frank ;
Sterrenburg, Monique ;
Smit, Janine ;
Abou-Setta, Ahmed M. .
HUMAN REPRODUCTION UPDATE, 2011, 17 (04) :435-435
[3]   Ovarian stimulation with HMG:: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin [J].
Albano, C ;
Felberbaum, RE ;
Smitz, J ;
Riethmüller-Winzen, H ;
Engel, J ;
Diedrich, K ;
Devroey, P .
HUMAN REPRODUCTION, 2000, 15 (03) :526-531
[4]   Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures [J].
Asimakopoulos, Byron ;
Nikolettos, Nikos ;
Nehls, Barbara ;
Diedrich, Klaus ;
Al-Hasani, Safaa ;
Metzen, Eric .
FERTILITY AND STERILITY, 2006, 86 (03) :636-641
[5]   Single dose GnRH agonist administration in the luteal phase of assisted reproduction cycles: is the effect dependent on the type of GnRH analogue used for pituitary suppression? [J].
Ata, B. ;
Urman, B. .
REPRODUCTIVE BIOMEDICINE ONLINE, 2010, 20 (01) :165-166
[6]   Gonadotropin-releasing hormone antagonists instead of agonists: a change for the better? [J].
Blumenfeld, Z .
FERTILITY AND STERILITY, 2001, 76 (03) :443-444
[7]   Gonadotropin-releasing hormone agonists versus antagonists for controlled ovarian hyperstimulation in oocyte donors: a systematic review and meta-analysis [J].
Bodri, Daniel ;
Sunkara, Sesh Kamal ;
Coomarasamy, Arri .
FERTILITY AND STERILITY, 2011, 95 (01) :164-169
[8]   Obstetrical and neonatal outcome after controlled ovarian stimulation for IVF using the GnRH antagonist ganirelix [J].
Boerrigter, PJ ;
de Bie, JJ ;
Mannaerts, BMJL ;
van Leeuwen, BP ;
Passier-Timmermans, DPJ .
HUMAN REPRODUCTION, 2002, 17 (08) :2027-2034
[9]   Large prospective, pregnancy and infant follow-up trial assures the health of 1000 fetuses conceived after treatment with the GnRH antagonist ganirelix during controlled ovarian stimulation [J].
Bonduelle, Maryse ;
Oberye, Janine ;
Mannaerts, Bernadette ;
Devroey, Paul .
HUMAN REPRODUCTION, 2010, 25 (06) :1433-1440
[10]  
Borm G, 2000, HUM REPROD, V15, P1490